We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Partners to Develop and Commercialize New Cancer Therapeutic Drugs

By LabMedica International staff writers
Posted on 21 Feb 2016
Print article
German and French biopharmaceutical companies have agreed to cooperate in the development and commercialization of new cancer therapeutics based on drugs that eliminate cancer cells by activating the TLR3 (Toll-like receptor 3) pathway.

Riboxx Pharmaceuticals (Radebeul, Germany) a biotech company developing Toll-like receptor (TLR) and RIG-I-like-Receptor (RLR) ligands, and Tollys SAS (Lyon, France), a biotech company developing new cancer therapeutic strategies, have signed a license agreement. The agreement grants Tollys exclusive global development and commercialization rights to the new APOXXIM drug development program.

TLR3 is a member of the Toll-like receptor (TLR) family, which plays a fundamental role in pathogen recognition and activation of innate immunity. TLRs are highly conserved from Drosophila to humans and share structural and functional similarities. They recognize pathogen-associated molecular patterns (PAMPs) that are expressed on infectious agents, and mediate the production of cytokines necessary for the development of effective immunity. RIG-I-like receptors are a type of intracellular pattern recognition receptor involved in the recognition of viruses by the innate immune system.

APOXXIM is a TLR3-ligand that eliminates cancer cells by activating the TLR3 pathway. It displays unique physical, chemical, and biological properties, with increased stability to degradation in body fluids such as human plasma. APOXXIM is manufactured according to Riboxx's unique, patented cGMP TENPORA Process.

Under the terms of the license agreement, Tollys will assume sole responsibility for global development and commercialization of APOXXIM. Riboxx will be responsible for manufacturing and supplying APOXXIM to Tollys.

Jacques Rohayem, CEO and CSO of Riboxx Pharmaceuticals said, "We are very thrilled to start this collaboration with Tollys, a company with a very strong scientific expertise in cancer therapy. This collaboration expands the portfolio of Riboxx drug development programs such as RIBOXXIM, RIBOXXOL and QUADROXXIM, mainly focusing on cancer immunotherapy."

Jacques-François Martin, president of Tollys, said, "Tollys is very pleased to start this collaboration towards the development of a new and unique therapeutic strategy in cancer. The potential of TLR3-ligands such as APOXXIM to treat cancer has been extensively studied in the past decades by scientists at Tollys, with a particular focus on TLR3-positive cancers."

Related Links:

Riboxx Pharmaceuticals


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.